var data={"title":"Chloramphenicol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Chloramphenicol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5867?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">see &quot;Chloramphenicol: Drug information&quot;</a> and <a href=\"topic.htm?path=chloramphenicol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Chloramphenicol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708673\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Blood dyscrasias: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of chloramphenicol. In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used when less potentially dangerous agents will be effective. It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such studies cannot be relied on to detect bone marrow depression prior to development of aplastic anemia. To facilitate appropriate studies and observation during therapy, it is desirable that patients be hospitalized.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149436\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Chloromycetin;</li>\n      <li>Chloromycetin Succinate;</li>\n      <li>Diochloram;</li>\n      <li>Pentamycetin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046221\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442236\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Follow serum concentrations closely to monitor for toxicity and efficacy in neonates due to variability in metabolism; use should be restricted to treatment of serious infections caused by susceptible organisms when less toxic drugs are ineffective (ie, resistance) or contraindicated. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Meningitis</b> (Tunkel, 2004):  IV: <b>Note:</b> Treat for a minimum of 21 days; use smaller doses and longer intervals for neonates &lt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PNA &le;7 days: 25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PNA 8-28 days: 25 mg/kg/dose every 12 hours or 50 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Severe infection:</b>  IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Weight-based dosing:</i> Limited data available (Prober, 1990):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\"> Patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&lt;1200 g: 22 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">1200-2000 g: 25 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Age-based dosing: </i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Premature neonate or term neonate with PNA &le;7 days: Dosing regimens variable: 25 mg/kg/dose  every 24 hours or initiation with a loading dose of 20 mg/kg followed in 12 hours by a maintenance regimen of 12.5 mg/kg/dose every 12 hours (Rajchgot, 1982; Rajchgot, 1983; Weiss, 1960) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Term neonate with PNA &gt;7 days: Dosing regimens variable:  25  mg/kg/dose every 12 hours or 12.5 mg/kg/dose every 6 hours (Rajchgot, 1983; Weiss, 1960)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Manufacturer's labeling:</i> <b>Note:</b> Frequency recommended by the manufacturer for this age group is higher than other expert recommendations, which generally recommend no more frequent than every 12 hours; monitor serum concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Preterm infants: 6.25 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Term infants:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">PNA &lt;14 days: 6.25 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">PNA &ge;14 days: 12.5 mg/kg/dose every 6 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046214\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">see &quot;Chloramphenicol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b>Note:</b> Follow serum concentrations closely to monitor for toxicity. Use should be restricted to treatment of serious infections when less toxic drugs are ineffective (ie, resistance) or contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> IV: 18.75-25 mg/kg/dose every 6 hours (Bradley, 2012; Kliegman, 2011; Tunkel, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe infections:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: 12.5 mg/kg/dose every 6 hours; in some cases higher doses up to 25 mg/kg/dose every 6 hours may be required; higher doses should be promptly decreased when able </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: 12.5-25 mg/kg/dose  every 6 hours; maximum daily dose: 4000 mg/<b>day</b> (AAP, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: <b>Systemic infections:</b> IV: 50-100 mg/kg/day in divided doses every 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Use with caution; monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Use with caution; monitor serum concentrations. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149410\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149395\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046226\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Administer over at least 1 minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Infuse over 30 to 60 minutes (Klaus 1998). In neonates, some centers have administered as an intermittent IV infusion over 15 minutes (Prober 1990) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130927\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149428\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046225\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of serious infections caused by susceptible organisms [eg, Salmonella, rickettsia, <i>H. influenza</i> (meningitis), or cystic fibrosis pathogens] when less toxic drugs are ineffective (ie,  resistance) or contraindicated (FDA approved in all ages) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149491\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Chloromycetin may be confused with chlorambucil, Chlor-Trimeton</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149488\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, delirium, depression, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, enterocolitis, glossitis, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Aplastic anemia, bone marrow depression, granulocytopenia, hypoplastic anemia, pancytopenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Optic neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Drug toxicity (Gray syndrome), fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149418\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to chloramphenicol or any component of the formulation; treatment of trivial or viral infections; bacterial prophylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149399\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: <b>[US Boxed Warning]: Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) have occurred after both short-term and prolonged therapy; do not use for minor infections or when less potentially toxic agents are effective. Monitor CBC frequently in all patients;</b> discontinue if evidence of myelosuppression. Irreversible bone marrow suppression may occur weeks or months after therapy. Avoid prolonged or repeated courses of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gray syndrome: Characterized by cyanosis, abdominal distention, vasomotor collapse (often with irregular respiration), and death. Reaction appears to be associated with serum levels &ge;50 mcg/mL (Powell 1982).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Use in premature and full-term neonates and infants has resulted in &ldquo;gray syndrome&quot; characterized by cyanosis, abdominal distention (with or without emesis), vasomotor collapse (often with irregular respiration), and death; progression of symptoms is rapid; prompt termination of therapy required. Reaction may result from drug accumulation caused by immature hepatic or renal function in neonates and infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149480\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149404\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13145&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Chloramphenicol (Systemic) may decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, chloramphenicol may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CefTAZidime: Chloramphenicol (Systemic) may diminish the therapeutic effect of CefTAZidime.  Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Fosphenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May increase the metabolism of Chloramphenicol (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Chloramphenicol (Systemic) may decrease the metabolism of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin B12: Chloramphenicol (Systemic) may diminish the therapeutic effect of Vitamin B12. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Chloramphenicol (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol (Systemic) may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: Chloramphenicol (Systemic) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50102719\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149420\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Chloramphenicol crosses the placenta producing cord concentrations approaching maternal serum concentrations. An increased risk of teratogenic effects has not been associated with the use of chloramphenicol in pregnancy (Czeizel 2000; Heinonen 1977). &quot;Gray Syndrome&quot; has occurred in premature infants and newborns receiving chloramphenicol. Chloramphenicol may be used as an alternative agent for the treatment of Rocky Mountain spotted fever in pregnant women although caution should be used when administration occurs during the third trimester (CDC [Biggs 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046220\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet counts (baseline and every 2 days during therapy), serum iron level, iron-binding capacity, periodic liver and renal function tests, serum drug concentration </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046224\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak: Neonates: 15 to 25 mcg/mL (Muhall 1983); Infants, Children, and Adolescents: 15 to 30 mcg/mL (Balbi 2004; Coakley 1992; Long 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough: 5 to 15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak: 10 to 20 mcg/mL (Ambrose 1984; Hammet-Stabler 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough: 5 to 10 mcg/mL (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Draw peak concentrations 0.5 to 1.5 hours after completion of IV dose; and trough immediately before next dose (Hammet-Stabler 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149398\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly binds to 50S ribosomal subunits of susceptible organisms preventing amino acids from being transferred to growing peptide chains thus inhibiting protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149417\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: To most tissues and body fluids (Ambrose 1984); good CSF and brain penetration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF concentration with uninflamed meninges: 21% to 50% of plasma concentration </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF concentration with inflamed meninges: 45% to 89% of plasma concentration </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol: V<sub>d</sub>: 0.6 to 1 L/kg (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol succinate: V<sub>d</sub>: 0.2 to 3.1 L/kg (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Chloramphenicol: ~60%; decreased with hepatic or renal dysfunction and 30% to 40% in newborn infants (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol: Hepatic to metabolites (inactive) (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol succinate: Hydrolyzed in the liver, kidney, and lungs to chloramphenicol (active) (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol: Oral: ~80% (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol succinate: IV: ~70%; highly variable, dependent upon rate and extent of metabolism to chloramphenicol (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 1 to 2 days: 24 hours; 10 to 16 days: 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Chloramphenicol: Infants: Significantly prolonged (Powell 1982); Children 4 to 6 hours; Adults: ~4 hours (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic disease: Prolonged (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~30% as unchanged chloramphenicol succinate in adults, 6% to 80% in children; 5% to 15% as chloramphenicol) (Ambrose 1984; Powell 1982)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046230\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 1 g injection: 2.25 mEq </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323057\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Chloramphenicol Sod Succinate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $46.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869368\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abefen (MX);</li>\n      <li>Aglomycetin (IN);</li>\n      <li>Alfa Cloromicol (EC);</li>\n      <li>Almycetin (PY);</li>\n      <li>Amphen (ET);</li>\n      <li>Anpechlor (PH);</li>\n      <li>Apiclox (BD);</li>\n      <li>Arifenicol (BR);</li>\n      <li>Armisetin (TR);</li>\n      <li>Beaphenicol (SG);</li>\n      <li>Biophenicol (IN);</li>\n      <li>Brocil (MX);</li>\n      <li>C-Phenicol (PH);</li>\n      <li>Cebenicol (VN);</li>\n      <li>Chemicetina (IT);</li>\n      <li>Chemycetin (ES);</li>\n      <li>Chloram-P (TH);</li>\n      <li>Chloramex (ID, QA, SA);</li>\n      <li>Chloranic (GR);</li>\n      <li>Chlorchol (ZA);</li>\n      <li>Chlorcol (ZA);</li>\n      <li>Chlornicol (ZW);</li>\n      <li>Chlornitromycin (BG);</li>\n      <li>Chloromycetin (AR, JP, MX, PH);</li>\n      <li>Chlorphen (ZA);</li>\n      <li>Clorafen (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cloramidina (ID);</li>\n      <li>Colsancetine (ID);</li>\n      <li>Decol (IN);</li>\n      <li>Enclor (SG);</li>\n      <li>Euchlor (VN);</li>\n      <li>Fencol (IN);</li>\n      <li>Fenicol (ID);</li>\n      <li>Gemysetin (TR);</li>\n      <li>Gerafen (PH);</li>\n      <li>Grafacetin (ID);</li>\n      <li>Helocetin (KR);</li>\n      <li>Kalmicetine (IN);</li>\n      <li>Kemicetine (BH, GB, HK, MT, PL, TR);</li>\n      <li>Labchlor (IN);</li>\n      <li>Levomycetin (RU);</li>\n      <li>Levomytsetyn (UA);</li>\n      <li>Medophenicol (TR);</li>\n      <li>Mephicetine (LB);</li>\n      <li>NeoFenicol (BR);</li>\n      <li>Neosechinbi (KR);</li>\n      <li>Ofenicol (PY);</li>\n      <li>Pharmaxin (BD);</li>\n      <li>Quemicitina (AR, BR);</li>\n      <li>Reclor (IN);</li>\n      <li>ShuEr (CN);</li>\n      <li>Sintomicetina (BR);</li>\n      <li>Soluparaxin (SA);</li>\n      <li>Solupraxin (QA);</li>\n      <li>Synthomycin (RU);</li>\n      <li>Type-S (LK);</li>\n      <li>Vixmicina (BR);</li>\n      <li>Xepanicol (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. <i>Clin Pharmacokinet</i>. 1984;9(3):222-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6375931/pubmed\" target=\"_blank\" id=\"6375931\">6375931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. <i>Clin Pharmacokinet</i>. 1988;14(4):217-240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/3292101/pubmed\" target=\"_blank\" id=\"3292101\">3292101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balbi HJ. Chloramphenicol: a review. <i>Pediatr Rev</i>. 2004;25(8):284-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/15286274/pubmed\" target=\"_blank\" id=\"15286274\">15286274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 19th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Center for Disease Control and Prevention (CDC). Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis - United States: a practical guide for physicians and other health-care and public health professionals. <i>MMWR Recomm Rep</i>. 2006. 55(RR-4):1-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/16572105/pubmed\" target=\"_blank\" id=\"16572105\">16572105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coakley JC, Hudson I, Shann F, Connelly JF. A review of therapeutic monitoring of chloramphenicol in patients with Haemophilus influenzae meningitis. <i>J Paediatr Child Health</i>. 1992;28(3):249-253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/1605978/pubmed\" target=\"_blank\" id=\"1605978\">1605978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czeizel AE, Rockenbauer M, S&oslash;rensen HT. A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy. <i>Eur J Epidemiol</i>. 2000;16(4):323-327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/10959939/pubmed\" target=\"_blank\" id=\"10959939\">10959939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hammett-Stabler CA and Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. <i>Clin Chem.</i> 1998;44(5):1129-1140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/9590397/pubmed\" target=\"_blank\" id=\"9590397\">9590397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, Shapiro S, <i>Birth Defects and Drugs in Pregnancy</i>, Littleton, MA: Publishing Sciences Group, Inc, 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long S, Pickering L, eds. Bacterial meningitis: antimicrobial therapy. <i>Principles and practice of pediatric infectious diseases.</i> 4th ed. Elsevier Inc; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol</i>. 1984;5(2):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6743732/pubmed\" target=\"_blank\" id=\"6743732\">6743732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulhall A, de Louvois J, Hurley R. Efficacy of chloramphenicol in the treatment of neonatal and infantile meningitis: a study of 70 cases. <i>Lancet</i>. 1983;1(8319):284-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6130304/pubmed\" target=\"_blank\" id=\"6130304\">6130304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plomp TA, Thiery M, Maes RA. The passage of thiamphenicol and chloramphenicol into human milk after single and repeated oral administration. <i>Vet Hum Toxicol</i>. 1983;25(3):167-172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6868331/pubmed\" target=\"_blank\" id=\"6868331\">6868331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell DA, Nahata MC. Chloramphenicol: new perspectives on an old drug. <i>Drug Intell Clin Pharm</i>. 1982;16(4):295-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/7040026/pubmed\" target=\"_blank\" id=\"7040026\">7040026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. <i>Pediatr Infect Dis J</i>. 1990; 9:111-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/2179837/pubmed\" target=\"_blank\" id=\"2179837\">2179837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajchgot P, Prober CG, Soldin S, et al. Initiation of chloramphenicol therapy in the newborn infant. <i>J Pediatr</i>. 1982; 101:1018-1021.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/7143156/pubmed\" target=\"_blank\" id=\"7143156\">7143156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajchgot P, Prober CG, Soldin SJ, et.al. Toward optimization of therapy in the neonate. <i>Clinical Pharmacology and Therapeutics</i>. 1983;33(5):551-555.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/6839629/pubmed\" target=\"_blank\" id=\"6839629\">6839629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, Taeschner W. Pharmacokinetic drug data. <i>Clin Pharmacokinet</i>. 1988; 15(4):254-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. <i>New Engl J Med</i>. 1960;262(16):787-794.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-pediatric-drug-information/abstract-text/13843700/pubmed\" target=\"_blank\" id=\"13843700\">13843700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13145 Version 175.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708673\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F149436\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046221\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442236\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046214\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F149410\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F149395\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046226\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130927\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F149428\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046225\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F149491\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F149488\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149418\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F149399\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F149480\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F149404\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F50102719\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F149420\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046220\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1046224\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F149398\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F149417\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1046230\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323057\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869368\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13145|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">Chloramphenicol: Drug information</a></li><li><a href=\"topic.htm?path=chloramphenicol-patient-drug-information\" class=\"drug drug_patient\">Chloramphenicol: Patient drug information</a></li></ul></div></div>","javascript":null}